Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q2 FY26 Earnings Presentation
38 slides from Neuland Laboratories's earnings presentation, Nov 7, 2025
Slide 1: Exchange filing cover letter
November 7, 2025 To BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Investors/Analys
Slide 2: Investor Presentation Q2FY26 & H1FY26
Neuland Laboratories Limited Investor Presentation Q2FY26 & H1FY26
Slide 3: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Table of Content
Table of Content Q2FY26 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q2FY26 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information 3
Slide 5: Q2FY26 & H1FY26 Highlights
Q2FY26 & H1FY26 Highlights 4
Slide 6: Management Commentary
Management Commentary SUCHETH DAVULURI “The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well posi
Slide 7: Q2 & H1 FY26 Business and Financial Highlights
Q2 & H1 FY26 Business and Financial Highlights CMS CMS revenues driven by commercial molecules. Growth in new projects orders which will be delivered over the course of this and next financial years GDS In Prime segment Ezetimibe, and Mirtazapine were the key molecules. Ezetimibe likely to drive gro
Slide 8: Q2FY26 Financial Highlights
Q2FY26 Financial Highlights Total Income EBITDA PAT EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 30.4% 25.2% 18.7% 20.8% 22.5% 516.1 17.3% 14.4% 10.2% 79.0 156.9 8.3% 101.4 75.2 401.9 96.5 335.8 315.2 300.6 4.6% 90.3 65.7 58.2 32.0 27.7 24.9 42.1 21.6 10.7 13.7 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q2FY25 Q3FY
Slide 9: H1 FY26 Financial Highlights
H1 FY26 Financial Highlights Total Income EBITDA PAT* EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 17.2% 20.0% 200.0 25.6% 24.4% 140.0 18.0% 180.0 25.0% 120.0 13.5% 16.0% 160.0 14.0% 100.0 816.7 20.0% 140.0 12.0% 101.6 759.6 130.2 199.1 80.0 194.3 120.0 10.0% 110.2 15.0% 100.0 85.9 60.0 8.0% 80.0 10.0% 6.0%
Slide 10: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio(x) ROCE % Fixed Asset Turnover (x) Debt to Equity (x) 3.1 32.8% 2.7 2.4 2.4 0.2 2.1 2.3 2.1 17.4% 1.9 21.3% 1.7 1.6 17.9% 0.1 0.1 0.1 9.7% 0.1 FY22 FY23 FY24 FY25 H1 FY26 FY22 FY23 FY24 FY25 H1 FY26 FY22 FY23 FY24 FY25 H1 FY26 FY22 FY23 FY24 FY25 H1 FY26 Parti
Slide 11: Key Operating Metrics Q2FY26
Key Operating Metrics Q2FY26 Segment revenue Top 10 & Top 5 Products Top 10 & Top 5 Customers Prime Specialty Top 10 Top 10 CMS Others Top 5 Top 5 97% 98% 96% 98% 6% 7% 7% 4% 5% 95% 91% 77% 76% 39% 34% 69% 72% 68% 64% 63% 69% 42% 44% 60% 47% 44% 19% 16% 23% 16% 11% 36% 33% 40% 32% 26% Q2FY25 Q3FY25
Slide 12: Key Operating Metrics H1FY26
Key Operating Metrics H1FY26 Segment Revenue Prime Specialty Top 10 & Top 5 Products Top 10 Top 10 & Top 5 Customers Top 10 CMS Others Top 5 Top 5 96% 97% 98% 6% 5% 88% 94% 95% 74% 71% 70% 62% 48% 54% 63% 59% 64% 59% 45% 46% 15% 13% 31% 28% H1FY25 H1FY26 Prime Specialty CMS Overall Company Prime Spe
Slide 13: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects Q2 FY26 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total 281 411 API 16 14 13 3 4 8 58 Intermediate 5 10 6 5 4 10 40 Grand Total 21 24 19 8 8 18 98 86 32 Q2 FY25 Pre-Clinical P-1 P-2 P-3 Pre-Reg
Slide 14: Company Overview
Company Overview 13
Slide 15: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 11,74,000 Liters Facilities Inspected by Supported 3
Slide 16: Key Facts
Key Facts 40+ 995+ 100+ 89% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 73 1174 KL 2039 Countries Served Active US DMFs API Manufacturing Employees Capacity 15
Slide 17: Board Of Directors
Board Of Directors Dr. Davuluri Mr. D. Sucheth Rao Mr. D. Saharsh Rao Dr. Christopher M. Ms. Pallavi Joshi Rama Mohan Rao Vice Chairman & Vice Chairman & Cimarusti Bhakru Executive Chairman Chief Executive Managing Director Non-executive Independent Officer Director Director Mr. Homi Rustam Mr. Pras
Slide 18: Key Milestones
Key Milestones Our Journey 2018 2019 2020 2021 2023 2024 Acquisition of Increased flow of projects 100 M+ revenue over Unit – III Crossed INR 10 bn US FDA audit advanced from CMS Japan. 75 live CMS projects Commercialization revenue. of Unit-I intermediates & Active emphasis on supply US FDA audit o
Slide 19: Our Global Presence
Our Global Presence* EUROPE 48% APAC NORTH AMERICA 3% 44% BD office in Princeton, New Jersey Since 2004 JAPAN 1% BD office in Tokyo, Japan Since 2007 LATAM INDIA 1% 1% Headquarters in MENA Hyderabad, India 3 Manufacturing 2% Units Manufacturing and Development partner to customers in over 80 Countri
Slide 20: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 258 kL Pashamylaram, Hyderabad 381 kL Gaddapotharam, Hyderabad 536 kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 6, 7 & 8
Slide 21: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs of which 3 • Several NCE APIs added in NDA or are for peptides. commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • De
Slide 22: Regulatory Filings
Regulatory Filings 73 32 10 17 25 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 281 ~499 30 995+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Polan
Slide 23: Financial Highlights FY2016-2025
Financial Highlights FY2016-2025 Rs. Cr FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 Total Income 511.6 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 1,497.3 EBITDA 81.5 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 342.8 EBITDA Margin 15.9% 18.1% 10.2% 9.2% 13.7% 17.1
Slide 24: Business Strategy
Business Strategy 23
Slide 25: Neuland Strategy Framework
Neuland Strategy Framework 04 Digitize to enable transparency, compliance, speed of decision making and ease of doing business 01 Invest in new technologies that are valued by our customers and help us differentiate vs. peers 05 Build a world-class talent pipeline and employee value proposition to e
Slide 26: Our Businesses
Our Businesses 25
Slide 27: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Have developed processes for over 100 • Non-competitive advantage (does not APIs with
Slide 28: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 29: Shareholder Information
Shareholder Information 28
Slide 30: Shareholding Details
Shareholding Details Share Information (as on 30th Sep 2025) NSE Ticker NEULANDLAB Others BSE Ticker 524558 33% Market Cap (Rs. Cr) 18,759.54 Promoters 33% % free-float 67.36% Free-float market cap (Rs. Cr) 12,636 Shares Outstanding 1,28,29,889 FII 3M Average Daily Traded Volume (ADTV) 91,812 21% DI
Slide 31: Annexure
Annexure 30
Slide 32: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Particulars (Rs Cr) Q2FY26 Q2FY25 YoY (%) Q1FY26 QoQ (%) Total Income 516.1 315.2 63.70% 300.6 71.70% EBITDA 156.9 65.7 138.80% 42.1 272.70% EBITDA Margin 30.40% 20.80% 960 bps 14.00% 1640 bps Exceptional Item* - - - - - Profit Before Tax* 129.0 48.5 166.00% 17.4
Slide 33: Revenue & PBT trend
Revenue & PBT trend Rs Cr Revenue 516 421 444 415 395 390 402 365 315 336 294 301 258 257 270 238 222 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 PBT* 130 128 129 121 110 104 92 84 53 49 39 39 28 24 18 13 17 Q2FY22 Q3FY22 Q4F
Slide 34: Vision and Values
We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration Vision and Values (— Innovation Innovative in everything we do (% Transparency Transparent and open in our communication (a Accountability Accountable for our delivery g Empathy Empathy in
Slide 35: Global peptide API market is poised to reach $14Bn by 2030
Global peptide API market is poised to reach $14Bn by 2030. Global peptide therapeutic /API market in $Bn Key market drivers Peptide therapeutic 125 167 Peptide API market to scale by ~$14 Market bn by 2030 driven mainly by rich peptide pipeline and increasing demand for GLP-1. Peptide API $14 marke
Slide 36: Sustainability Framework
Sustainability Framework Our Key Goals (included in our Executives’ and Focus Our Priorities Our Commitments Goal Area Leaders’ Balanced Scorecard) • Effluent and Waste3’4 • Reduce both direct and indirect Direct emissions • FY 2033-34: 58.8% reduction in Scope 1 and 2. • Water3’4 emissions. (Scope
Slide 37: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 38: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: ir@Neulandlabs.com Ravi Udeshi / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com